Metrion Biosciences appoints Lee Patterson as CEO

Metrion Biosciences (“Metrion”), the specialist preclinical contract research organization (CRO) and a leader in ion channel screening, today announced the appointment of Lee Patterson as its new CEO, effective from 2nd December 2024. An experienced life sciences and CRO executive, Lee will guide the Company as it seeks to execute an ambitious growth strategy, enhancing its specialist services and expanding further in key global markets. He succeeds Dr Andrew Southan, who has decided to step down as CEO after five years in the post.

A renowned leader in the sector, Lee Patterson specializes in steering preclinical CROs to implement robust and effective plans for long-term commercial growth. Previously CEO at Charnwood Discovery, a provider of integrated drug discovery services with a global biotech and pharma client base, he led the company through its successful acquisition by Concept Life Sciences in October 2024. Prior to this, Lee served as Chief Operating Officer at Quanticate, a global biometrics CRO, and Chief Operating Officer at Concept Life Sciences. He also held several executive roles at Covance/Labcorp, the most recent being Executive Director, Global Operations and Early Development Management Office.

Lee will join recently appointed CCO Dr Chris Mathes as the latest addition to Metrion’s senior leadership team1. Working closely alongside Chris and the broader management team, Lee’s C-suite level expertise and experience will support Metrion to bolster its global commercial presence and scientific capabilities.

Outgoing CEO Dr Andrew Southan has led Metrion successfully since 2019, more than doubling revenues over that time and overseeing the Company’s growth in staffing, laboratory facilities and international client base. He also led the Company’s successful £3.7M equity financing round in December 2023.

On behalf of the Board and management team, I would like to thank Andy Southan for his dedicated leadership over the last five years, in particular establishing Metrion’s reputation as a high quality, specialist CRO and a leading center of expertise in ion channel biologyAt the same time, I am delighted to welcome Lee Patterson to the Company. His experience of leading commercial CROs and his expertise in enhancing operational efficiencies are both outstanding and we look forward to working with him to continue Metrion’s growth as a specialist CRO serving global markets.

Keith McCullagh, Chairman, Metrion Biosciences

Lee Patterson, CEO, Metrion Biosciences, commented: “Metrion Biosciences has built an impressive reputation in ion channel drug discovery, with proven commitment to outstanding customer service and world class science. I am excited to join this talented team and look forward to working with them to enhance and expand our specialized services to meet the needs of our clients worldwide.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Metrion Biosciences Limited. (2024, November 26). Metrion Biosciences appoints Lee Patterson as CEO. News-Medical. Retrieved on December 05, 2024 from https://www.news-medical.net/news/20241126/Metrion-Biosciences-appoints-Lee-Patterson-as-CEO.aspx.

  • MLA

    Metrion Biosciences Limited. "Metrion Biosciences appoints Lee Patterson as CEO". News-Medical. 05 December 2024. <https://www.news-medical.net/news/20241126/Metrion-Biosciences-appoints-Lee-Patterson-as-CEO.aspx>.

  • Chicago

    Metrion Biosciences Limited. "Metrion Biosciences appoints Lee Patterson as CEO". News-Medical. https://www.news-medical.net/news/20241126/Metrion-Biosciences-appoints-Lee-Patterson-as-CEO.aspx. (accessed December 05, 2024).

  • Harvard

    Metrion Biosciences Limited. 2024. Metrion Biosciences appoints Lee Patterson as CEO. News-Medical, viewed 05 December 2024, https://www.news-medical.net/news/20241126/Metrion-Biosciences-appoints-Lee-Patterson-as-CEO.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Metrion and LifeArc extend neuroscience-focused ion channel drug discovery collaboration